Plus   Neg

Roche' Alecensa Increases OS Rate For People With ALK-positive Non-small Cell Lung Cancer

Roche (RHHBY) said that its phase III ALEX study showed an increased five-year survival rate with Alecensa, compared with crizotinib, in people living with anaplastic lymphoma kinase or ALK-positive non-small cell lung cancer or NSCLC.

The company said the data confirmed the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials.

The updated results from the ALEX study show a five-year survival rate of 62.5% in the Alecensa treatment group, compared to 45.5% with crizotinib.

The safety profile of Alecensa remains favourable and consistent with previous data, with no new safety signals identified, the company said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT